Key facts
- This page summarizes Cheng Liu's Form 4 filing for Estrella Immunopharma, Inc. (ESLA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2025, 16:30.
Cheng Liu - 30 Oct 2024 Form 4 Insider Report for Estrella Immunopharma, Inc. (ESLA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ESLA
- Reported as of
- 30 Oct 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2025, 16:30:20 UTC
- Prior SEC filing
- 10 Oct 2023
- Next SEC filing
- 26 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cheng Liu
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cheng Liu filed Form 4 for Estrella Immunopharma, Inc. (ESLA) on 14 Feb 2025.
Change
- Previous filing in this sequence was filed on 10 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ESLA
transaction
Derivative
Incentive Share Option
Award
- Transaction value
- Shares
- +490,796
- Change %
- Price
- Shares after
- 490,796
- Date
- 30 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 490,796
- Exercise price
- $0.8150
- Footnotes
- F1, F3
ESLA
transaction
Derivative
Nonstatutory Share Option
Award
- Transaction value
- Shares
- +509,204
- Change %
- Price
- Shares after
- 509,203
- Date
- 30 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 509,204
- Exercise price
- $0.8150
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares.
Footnote F2
The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.
Footnote F3
On October 30, 2024, the Board of the Company awarded Mr. Liu a nonstatutory shares option grant of 509,204 shares.
Footnote F4
The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.